Stonepine Capital Management’s AYTU BioPharma AYTU Stock Holding History

Stonepine Capital Management’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Buy	912,921 +120,632	+15%	+$285K	1.11%	29
2026 Q1	$2.16M	Sell	792,289 -21,415	-3%	-$54.8K	0.87%	21
2025 Q4	$2.12M	Sell	813,704 -78,151	-9%	-$175K	1.54%	21
2025 Q3	$1.68M	Buy	891,855 +79,179	+10%	+$183K	1.36%	19
2025 Q2	$1.77M	Buy	812,676 +348,955	+75%	+$542K	1.74%	16
2025 Q1	$795K	Buy	463,721 +56,172	+14%	+$81.7K	0.77%	27
2024 Q4	$693K	Sell	407,549 -93,409	-19%	-$171K	0.56%	35
2024 Q3	$1.18M	Buy	500,958 +28,489	+6%	+$73.8K	0.74%	25
2024 Q2	$1.38M	Hold	472,469	–	–	1.26%	15
2024 Q1	$1.44M	Hold	472,469	–	–	1.14%	14
2023 Q4	$1.34M	Buy	472,469 +100	+0%	+$275	0.58%	14
2023 Q3	$1.28M	Hold	472,369	–	–	0.42%	23
2023 Q2	$756K	Buy	+472,369	New	+$927K	0.27%	21
2021 Q2	–	Sell	-18,146	Closed	-$2.76M	–	28
2021 Q1	$2.76M	Sell	18,146 -51,793	-74%	-$8.22M	1.49%	18
2020 Q4	$8.37M	Buy	+69,939	New	+$12.7M	6.4%	4

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Stonepine Capital Management's AYTU Position: Q2 2026 in Review

Stonepine Capital Management increased its AYTU BioPharma (AYTU) stake by 15% in Q2 2026, buying an estimated $285K and bringing the position to 912,921 shares worth $1.96M. The position accounts for 1.11% of the portfolio, ranked #29.

Stonepine Capital Management first reported a position in AYTU in Q4 2020 and has held it in 15 quarters since. The position peaked at $8.37M in Q4 2020. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

Stonepine Capital Management held 912,921 shares of AYTU BioPharma worth $1.96M as of Q2 2026.
Stonepine Capital Management bought 120,632 AYTU BioPharma shares in Q2 2026, an estimated $285K.
AYTU BioPharma made up 1.11% of Stonepine Capital Management's portfolio in Q2 2026, its #29 holding.
Stonepine Capital Management first reported a position in AYTU BioPharma in Q4 2020 and has held it in 15 quarters since.
Stonepine Capital Management's AYTU BioPharma position peaked at $8.37M in Q4 2020.
38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.